
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Discovery
Sponsor : REMEDIS
Deal Size : Undisclosed
Deal Type : Collaboration
Life Biosciences Collaborates to Expand Pipeline of Cellular Rejuvenation Therapies
Details : Life Biosciences signed an MOU with REMEDIS to advance its partial epigenetic reprogramming platform for multicentric anti-aging therapies.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
July 22, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Discovery
Sponsor : REMEDIS
Deal Size : Undisclosed
Deal Type : Collaboration

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Study Phase : Preclinical
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
Details : Forge will help to advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications by providing cGMP manufacturing and development services for its novel AAV ge...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Ophthalmology
Highest Development Status : Preclinical
Recipient : Forge Biologics
Deal Size : Undisclosed
Deal Type : Partnership
